ProCE Banner Activity

Updated Results From Phase I Trial of AMG 420, an Anti-BCMA Bispecific T-Cell Engager, in Patients With Relapsed/Refractory Multiple Myeloma

Slideset Download
Conference Coverage
The BiTE construct AMG 420 induces rapid clinical responses, including MRD negativity, in patients with relapsed/refractory multiple myeloma.

Released: June 04, 2019

Expiration: June 02, 2020

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro